0001209191-23-058574.txt : 20231213
0001209191-23-058574.hdr.sgml : 20231213
20231213213213
ACCESSION NUMBER: 0001209191-23-058574
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231002
FILED AS OF DATE: 20231213
DATE AS OF CHANGE: 20231213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mackaness James H
CENTRAL INDEX KEY: 0001422484
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36593
FILM NUMBER: 231485417
MAIL ADDRESS:
STREET 1: 1212 TERRA BELLA AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC
CENTRAL INDEX KEY: 0001484565
STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
IRS NUMBER: 770523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
BUSINESS PHONE: 650-213-8444
MAIL ADDRESS:
STREET 1: 203 REDWOOD SHORES PARKWAY
STREET 2: SUITE 500
CITY: REDWOOD CITY
STATE: CA
ZIP: 94065
FORMER COMPANY:
FORMER CONFORMED NAME: Capnia, Inc.
DATE OF NAME CHANGE: 20100219
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-10-02
0
0001484565
SOLENO THERAPEUTICS INC
SLNO
0001422484
Mackaness James H
203 REDWOOD SHORES PKWY, STE 500
REDWOOD CITY
CA
94065
0
1
0
0
Chief Financial Officer
0
Common Stock
2023-10-02
4
M
0
2666
4.50
A
36236
D
Common Stock
2023-10-02
4
M
0
2143
1.75
A
38379
D
Common Stock
2023-10-02
4
M
0
3500
2.50
A
41879
D
Warrants (right to buy)
4.50
2023-10-02
4
M
0
2666
0.00
D
2022-03-31
2027-03-31
Common Stock
2666
0
D
Warrants (right to buy)
1.75
2023-10-02
4
M
0
2143
0.4425
D
2023-05-08
Common Stock
2143
0
D
Warrants (right to buy)
2.50
2023-10-02
4
M
0
3500
0.4425
D
2023-05-08
Common Stock
3500
0
D
The number of shares reported as beneficially owned following the reported transaction is as of October 2, 2023.
The Warrants expire upon the earlier of (i) 30 days following announcement of positive top-line data from the randomized withdrawal period of Study C602, an open-label extension study pertaining to Diazoxide Choline Extended-Release tablets (DCCR) for the treatment of Prader-Willi syndrome (PWS), or (ii) November 8, 2026.
The Warrants expire upon the earlier of (i) 30 days following receipt of U.S. Food and Drug Administration approval of DCCR for the treatment of PWS or (ii) November 8, 2026.
/s/ James Mackaness
2023-12-13